Arrhythmias & electrophysiology

Bilateral Cardiac Sympathetic Denervation for Refractory Multifocal Premature Ventricular Contractions in Patients With Nonischemic Cardiomyopathy

JACC Clin ElectrophysiolPublished Case series

Authors' conclusion

BCSD is effective for the management of refractory PVCs and ventricular tachycardia who have failed previous ablation therapy.

Study context

Population
Patients with >5% premature ventricular contraction (PVC) burden and nonischemic cardiomyopathy (NICM) who failed medical and ablation therapies
Participants
43 patients
Exposure
Post-BCSD vs pre-BCSD
Outcome
PVC burden resolution, improvement in left ventricular ejection fraction (LVEF), and cessation of AADs
Follow-up
1-year follow-up
Methodological detailssingle-group, pre-post comparison
  • Single-group
  • Pre-post comparison

Main finding

As reported in the abstract

AAD use

P < 0.001

OutcomePre-BCSDPost-BCSDP value
PVC burden23.7% ± 9.9%1.3% ± 1.1%P < 0.001
LVEF38.7% ± 7.8%46.3% ± 9.5%P < 0.001

Observational data: associations, not effects.

Further findings

ICD therapies

P < 0.001

OutcomePre-BCSDPost-BCSDP value
NYHA functional classMean2.5 (SD 0.5)1.4 (SD 0.2)P < 0.001
No mortality or major complications · 1-year follow-upRemaining patients still within first year postprocedure— not stated in the abstract81.4%

— not stated in the abstract

No mortality or major complications · 1-year follow-up

Free of mortality or major complications
81.4% (n = 35)
  • Remaining patients still within first year postprocedure

Safety

Major intraoperative complications (hemothorax and chylothorax)

Major intraoperative complications
4.7%

Original publication

Bilateral Cardiac Sympathetic Denervation for Refractory Multifocal Premature Ventricular Contractions in Patients With Nonischemic Cardiomyopathy. JACC Clin Electrophysiol. Published 8 November 2023. doi:10.1016/j.jacep.2023.09.014

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.